AGENTA Therapeutics

Meet the Founders

Former founder and CEO of INOVIO Pharmaceuticals (NASDAQ:INO).
Took INOVIO public and grew it from a start up into a public biotech with >350 FTEs and a peak market capitalization of $5.3 billion in 2020.
Recruited and built high-performing teams with strong corporate culture.
Fundraised >$1.0 billion in capital at INOVIO Pharmaceuticals and VGX Pharmaceuticals.
Directed $1.2 billion major product out-licensing deals with large pharma companies (AstraZeneca and Roche).
Brought in >$350 million in non-dilutive funding through grants/contracts.
Advanced new compounds tested via clinical stages for FDA and regulatory agency approval.

Executive VP and W.W. Smith Endowed Chair in Cancer Research, The Wistar Institute
Professor Emeritus, University of Pennsylvania
Co-founder and Director of INOVIO Pharmaceuticals
His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies.
Weiner and his lab have received several awards/honors for their accomplishments:
Vaccine Industry Associations Outstanding Academic Research Laboratory (2015 & 2016)
Top 20 Translational Research Laboratories of the Year (Nature Biotech 2016, 2017 & 2018)
2014 Stone family Award for Cancer Research
Top 40 most influential vaccine scientists in 2014
2011 NIH Directors Translational Research Award
American Association for the Advancement of Science since 2011
President of the International Society for Vaccines (2018 ~ 2020)

Former VP, Analytical Science & Immunology of INOVIO Pharm.
Former VP, R&D of Imunon Pharma.
Former Associate Research Professor at the University of Pennsylvania
Led multiple immunology and analytical programs for Phase I through Phase III clinical trials for infectious diseases and oncology

Former Chief Medical Officer of Sensei Biotherapeutics
Former Chief Commercial R&D Officer at City of Hope and Vice President at INOVIO
Held clinical development lead roles at Merck responsible for KEYTRUDA® development in multiple indications

Former Director of National Cancer Institute
Oversaw the development of numerous anti-cancer and anti-viral therapeutic agents
Has served on the boards of numerous successful biotech companies